Wednesday, July 30, 2025 7/30/2025

Targeting ER Stress Pathway Using Sodium 4-Phenylbutyrate for the Treatment of POAG

Award Number: R01EY028616
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2018
PERIOD OF PERFORMANCE END DATE: 12/31/2022

Group Awards By:

View Award Description

Targeting ER Stress Pathway Using Sodium 4-Phenylbutyrate for the Treatment of POAG - Abstract Primary open angle glaucoma (POAG), a major cause of irreversible blindness, is often associated with elevated intraocular pressure (IOP) due to increased aqueous humor outflow resistance at the trabecular meshwork (TM). The pathological mechanisms leading to glaucomatous TM damage and IOP elevation are poorly understood. We have previously linked protein misfolding and endoplasmic reticulum (ER) stress to development of glaucomatous TM damage and IOP elevation. Importantly, we demonstrated that targeting abnormal myocilin accumulation and ER stress via small chemical chaperone, sodium 4-phenylbutyrate (PBA) rescues mouse model of myocilin glaucoma, which accounts for ~4% of general POAG. Our long-term goal is to determine whether PBA can be used for the treatment of the general POAG cases. Increased accumulation of extracellular matrix (ECM) due to reduced activity of matrix metalloproteinases (MMPs) that degrade extracellular ECM is implicated in the pathophysiology of general POAG. We have recently demonstrated that increased ECM accumulation induces chronic ER stress in the TM of POAG. Moreover, our preliminary studies suggest that PBA reduces ECM accumulation via induction and activation of MMPs. It is our central premise that increased ECM accumulation induces chronic ER stress, leading to TM dysfunction and IOP elevation in POAG and PBA reduces ECM accumulation and ER stress via induction and activation of MMPs. To test this hypothesis, we will utilize primary human TM cells and mouse models of glucocorticoid (GC) or TGFβ2-induced ocular hypertension and human perfusion cultured POAG eyes. Both GC or TGFβ2 are known to be involved in the pathophysiology of glaucomatous TM damage via increased outflow resistance and increased ECM accumulation in the TM. Based on our preliminary data that GCs activate TGFβ2 signaling, we will examine whether TGFβ2 signaling regulates GC-induced glaucoma (Aim1). Considering the major role of TGFβ2 in the pathogenesis of POAG, we will next determine whether TGFβ2 induces chronic ER stress, leading to TM dysfunction and IOP elevation via genetic knockdown of key mediators of chronic ER stress (Aim 2). In Aim 3, we will determine whether PBA improves outflow facility and prevents TGFβ2-induced ocular hypertension in mice and ex-vivo human perfusion cultured eyes. We will also determine whether PBA reduces elevated IOP via its non-chaperonin activity on induction and activation of MMPs. The proposed studies will provide pathological mechanisms of TM dysfunction and target these pathologies via PBA for the treatment of general POAG. Importantly, these studies will provide an important foundation for planned clinical trials for PBA at the University of Iowa.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2021	THE UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH	3500 CAMP BOWIE BLVD	FORT WORTH	TX	76107	TARRANT	USA	Vision Research	000	4	10/25/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2021	UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH	3500 CAMP BOWIE BLVD	FORT WORTH	TX	76107	TARRANT	USA	Vision Research	000	4	8/10/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $354,050 )
2021	2021	UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH	3500 CAMP BOWIE BLVD	FORT WORTH	TX	76107	TARRANT	USA	Vision Research	000	4	6/23/2021	NON-COMPETING CONTINUATION	$354,050
														Subtotal = $354,050

Issue Date FY: 2020 ( Subtotal = $361,320 )
2020	2020	UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH	3500 CAMP BOWIE BLVD	FORT WORTH	TX	76107	TARRANT	USA	Vision Research	000	3	6/25/2020	NON-COMPETING CONTINUATION	$361,320
														Subtotal = $361,320

Issue Date FY: 2019 ( Subtotal = $365,000 )
2019	2019	UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH	3500 CAMP BOWIE BLVD	FORT WORTH	TX	76107	TARRANT	USA	Vision Research	000	2	6/20/2019	NON-COMPETING CONTINUATION	$365,000
														Subtotal = $365,000

Issue Date FY: 2018 ( Subtotal = $365,000 )
2018	2018	UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH	3500 CAMP BOWIE BLVD	FORT WORTH	TX	76107	TARRANT	USA	Vision Research	000	1	9/19/2018	NEW	$365,000
														Subtotal = $365,000

Grand Total All Awards = $1,445,370

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting ER Stress Pathway Using Sodium 4-Phenylbutyrate for the Treatment of POAG

Award Number: R01EY028616

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2018

PERIOD OF PERFORMANCE END DATE: 12/31/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer